Trial Profile
A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs RG 4733 (Primary) ; Vismodegib (Primary)
- Indications Alveolar soft part sarcoma; Brain metastases; Chordoma; Clear cell sarcoma; Gastrointestinal stromal tumours; Liposarcoma; Sarcoma
- Focus Adverse reactions; Therapeutic Use
- 02 Feb 2022 Results assessing efficacy of concurrent inhibition of Notch and Hedgehog signaling using the gamma secretase inhibitor (GSI) RO4929097 and the smoothened antagonist vismodegib in unresectable or metastatic sarcoma.published in the Clinical Cancer Research
- 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Nov 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.